Werden DPP-4-Hemmer Sulfonylharnstoffe in der Therapie des Typ-2-Diabetes ersetzen? Pro

Schlüsselwörter

Dipeptidyl-Peptidase-4-(DPP-4)Hemmer - Glucagon-like Peptid-1 - Sulfonylharnstoffe - orale Antidiabetika - ischämisch Präkonditionierung

Keywords

DPP-4 inhibitor - glucagon-like peptide-1 - sulfonylureas - oral antidiabetic drugs - ischemic preconditioning

Literatur

• 1 Filozof C, Gautier J F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone:.  Diabet Med. 2010;  27 318-326
• 2 Garratt K N, Brady P A, Hassinger N L. et al . Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.  J Am Coll Cardiol. 1999;  33 119-124
• 3 Matthews D R, Dejager S, Åhren B. et al . Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain.  Diabetes Obes Metab. 2010;  12 780-789
• 4 Nauck M A, Heimesaat M M, Behle K. et al . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.  J Clin Endocrinol Metab. 2002;  87 1239-1246
• 5 Seck T, Nauck M, Sheng D. et al . Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin.  Int J Clin Pract. 2010;  64 562-576